The second largest pharmaceutical company in France: Servier Laboratoires

Laboratoires Servier, a French Servier pharmaceutical company, was founded in 1954, Headquartered in France Suresnes， 22000 full-time employees, second only to France Sanofi The second largest pharmaceutical company.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/servier.html

Encyclopedia of Servier Laboratoires of Servier

Servier Laboratories is a privately owned pharmaceutical company, mainly engaged in the research and development of drugs for the treatment of heart disease, cancer, rheumatism, diabetes and clinical depression. It mainly involves cardiovascular diseases (such as coronary artery disease, venous disease, thrombosis, hypertension), tumors (cytotoxic drugs, angiogenesis, cell cycle, apoptosis), osteoporosis (disease) - osteoarthritis, metabolic disease/type 2 diabetes, central nervous system diseases (depression, anxiety, schizophrenia, cerebral ischemia, cognitive impairment), etc. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/servier.html

Servier Laboratories operates on five continents in 140 countries and has R&D centers in Suresnes, Croissy, Orl é ans, Gidy, Bolbec and Budapest, Hungary; It also has 19 international therapeutic research centers (ICTRs) in Germany, France, the United Kingdom, Canada, Australia, Japan, Singapore, Poland, Spain, Italy, Hungary, Belgium, the Czech Republic, South Korea, Argentina, Brazil, China, Russia and Scandinavia. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/servier.html

Servier has 92% of its drugs used as prescription drugs in various countries, and 44 new chemical entities targeting the following therapeutic fields are under development: cardiovascular disease, central nervous system and psychiatry, cancer research, diabetes and metabolism, and rheumatology. include: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/servier.html

Leading products : The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/servier.html

• Gliclazide (Diamicron, Diamicron MR) - antidiabetic drug, Damekang ®
• Indepamide (Fludex SR, Natrilex SR, Lozide) - diuretic
• Ivabradine (Procoralan) - anti angina drug
• Perindopril (Coversyl) - ACE inhibitor
• Stratium ranelate (Protelos) - osteoporosis drug
• Tianeptine (Stablon) - antidepressant, which indirectly changes the activity of AMPA and NMDA glutamate receptor
• Trimetazidine (Vastarel MR) - anti angina drug

Other products : The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/servier.html

• Agomelatine (Valdoxan, Melitor, Thymanax)
• Almitrine (Duxil, Vectarion)
• Amineptine (Survector, Maneon, Directim)
• Benfluorex (Mediaxal)
• Carbutamide (Glucidoral)
• Daflon 500
• Fenspiride (Pneumorel)
• Fotemustine (Muphoran)
• Fusafungine (Locabiotal)
• Gliclazide (Diamicron) - Damekon ® (Diamicron) (Gliclazide sustained-release tablets)
• Indapamide (Natrilix, Tertensif, Lozide)
• Perindopril (Coversyl, Prestarium)
• Perindopril/indapamide (Preterax, Coversyl Plus)
• Piribedil (Trivastal retard)
• Rilmenidine (Hyperium)
• Sodium alginate (Pseudophage)
• Sulbutiamine (Arcalion)
• Tertatolol (Artex)
• Vitamins (Vitathion)

Cooperative development project of Servier Laboratoires

Servier, as an internal research and development activity, undertakes collaborative and cooperative research projects with industrial and academic partners. InnoMed PredTox is an example in the field of non clinical safety assessment. The company is expanding its activities within the framework of the EFPIA Innovative Drugs Initiative and the European Commission. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/servier.html

In addition, Servier is also engaged in research and licensing cooperation in the pharmaceutical and biotechnology industries. These include: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/servier.html

• Heart disease: XENTION (UK, 2013), AMGEN (USA, 2013), MIRAGEN (USA, 2011), ARMGO (USA, 2006)
• Diabetes field: INTARCIA (USA, 2014)
• Metabolic diseases: INTERCEPT - TGR5 agonists (USA, 2011), GENFIT (FR, 2004)
• Neurology disease field (MS): GENEURO (CH, 2014)
• Tumor field: CTI BIOPHARMA (USA, 2014), NOVARTIS (CH, 2014), CELLECTIS (FR, 2014), NERVIANO (IT, 2013), EOS (IT) / CLOVIS (USA, 2012), BIOINVENT (SE, 2012), MACROGENICS (USA, 2011/12), GALAPAGOS (NDL, 2011), BIOREALITES (FR, 2011), PHARMACYCLICS - HDAC inhibitor (USA, 2009, 2015 AbbVie Acquired with US $21 billion), HYBRIGENICS (FR, 2007/2011) VERNALIS (UK, 2007/2011)
• In the field of orphan disease/heart disease/diabetes: XOMA (USA, 2010)
• Osteoporosis and osteoarthritis: OSTEOLOGIX (USA, 2010), GALAPAGOS (NDL, 2010), KAROS (USA, 2010), NORDIC BIOSCIENCE (DK, 2006/2010)

Servier History Encyclopedia of Servier Laboratoires

In 1954, 30 year old doctor of medicine and pharmacy Jacques ▪ servier Jacques Servier founded a pharmaceutical company with only 9 employees in Orl é ans, France. It has now developed into a leading independent pharmaceutical enterprise in France The second largest French pharmaceutical enterprise It has 20000 employees and business footprints in 140 countries around the world. Jacques ▪ servier (Jacques Servier) The reason why he has achieved such outstanding achievements lies in his love for the industry, his "belief" in medical research, his profound analysis of the needs of others, and his desire for development and sharing. In a word, he is full of vigorous impetus. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/servier.html

servier Company memorabilia ：

• 1954 , took over a small pharmaceutical production company in Orl é ans (Orleans).
• One year later , the company first released two drugs: antihypertensive drugs and antidiabetic drugs.
• 1956 , built the first production unit in Fleury les Aburais.
• Stimulated by research work, after several years of development, the company is getting better.
• 1960 Servier Research Center was established in Suresnes.
• 1962 , becoming the first modern industrial chemical group in Normandy Bolbec.
• 1964 , opened its first branch in London, and embarked on the journey of internationalization.
• 1972 In Loiret (Loire Province), Gidy's "hometown of factories" was established as a window for the group to show itself to the society.
• 1975-1980 And entered North America, Latin America, China and Russia for the first time.
• 1984 The first international therapeutic research center (ICTR) was established in London.
• 1988 Scrip nominated Servier as the most creative pharmaceutical enterprise in the world.
• 1989 The R&D Center has employed 1000 researchers.
• 1990 The first pharmaceutical factory outside France started in Arklow, Ireland.
• 1994 The second Servier Research Center was established in Croissy.
• 1995 , the first external expansion, acquiring 51% of the capital of the Hungarian pharmaceutical company Egis Pharmaceutical.
• 1996 ， Largest in Europe The foundation of Gidy clinical supply factory was laid.
• 1997 , second external expansion and acquisition of Poland's Alparm.
• 2001 The 10th ICTR was established in Brazil, followed by Poland and China.
• 2002 Servier was awarded the Galien Award for his innovative achievements in the research field.
• 2002 Servier subsidiary, founded in 1996, was restarted in Biogaran as a manufacturer of generic drugs. By 2003, it had developed into a leader in the French generic drug market.
• 2002 On September 12, a pharmaceutical factory was opened in Tianjin, China.
• 2003 , opened a pharmaceutical factory in Nouasseur, Morocco.
• Same year Servier became the largest pharmaceutical group in Russia. There are more than 15000 cooperation units in the world.
• 2006 Servier laid the foundation in Lady Orl é ans, and a new drug production unit was born, covering an area of 35000 square meters.
• 2018 , April 16, Shire Announced an agreement with French Servier to sell its tumor business for US $2.4 billion.
• In 2020, Servier acquired Symphogen.
• In March 2021, Servier was sentenced to a fine of 2.7 million euros for serious fraud and manslaughter, but was acquitted of fraud charges. The court also ordered the company to pay hundreds of millions of euros in compensation to 6500 plaintiffs, and one of its main managers was sentenced to four years of probation. French medical institution ANSM was fined 300000 euros due to poor supervision.

Servier contributes 57% of the trade balance of the French pharmaceutical industry. Servier is also the 25th largest pharmaceutical enterprise in the world. It has established its brand for French pharmaceuticals in Russia, Brazil, Turkey and China, and continues to invest in France. It is a special partner of Inserm, CNRS and Institut Curie. 92% of its original research drugs are sold outside France. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/servier.html

Servier Laboratoires Servier US equity investment

Unlisted company 。